Cannabis spray firm speeds European expansion
GW Pharmaceuticals, the Cambridge company exploiting a cannabis-based spray for use in several medical areas, is seeking to expand sales into 10 new European countries.
The company is also hiring at its new offices in Histon, Cambridge UK.
It has submitted an application under the European Mutual Recognition Procedure (MRP) to seek to expand the marketing authorisation for Sativex® to a number of additional European member states.
This follows successful completion of a previous MRP earlier this year in which recommendation for approval of Sativex® was obtained from regulatory authorities in Germany, Italy, Denmark, Sweden, Austria and the Czech Republic. Sativex received approval in the UK and Spain in 2010.
The complete list of new territories to be targeted is being finalised. It is expected to include around 10 new countries and will mean that if this MRP process is successful, approaching 20 European countries will have recommended approval of Sativex.
GW expects the new MRP process to complete around mid-2012.
Sativex oromucosal spray is a first in class endocannabinoid system modulator for the treatment of spasticity in MS and a wide range of therapeutic indications. The product is also in Phase III clinical development as a treatment for cancer pain.
Headed by biotech veteran Geoffrey Guy, GW was founded in 1998 and listed on AIM in 2001. It is licensed by the UK Home Office to work with a range of controlled drugs for medical research purposes.
GW is now looking to recruit a full-time permanent staff member to the Pharmacovigilance team which will be based at GW’s new offices in Histon, Cambridge.
• PHOTOGRAPH SHOWS: Geoffrey Guy